1 completed, 1 enrolling by invitation. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 1, Enrolling by invitation 1 |
Follow Heart Failure and Reduced Ejection Fraction: new trials by email Literature Review of Heart Failure and Reduced Ejection Fraction trials Research Report on Heart Failure and Reduced Ejection Fraction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRIMA-HF: Predicting Myocardial Recovery in Heart Failure Using Cardiac Imaging HAI-HF: High Dosing vs. Standard Dosing Adenosine During Myocardial Perfusion in Heart Failure HAI-HF: Adenosine Stress [¹⁵O]H₂O PET Imaging, Two different doses of adenosine - Heart Failure and Reduced Ejection Fraction, Heart Failure | Phase 4 | Enrolling by invitation | Gødstrup Hospital | 180 | 2025-12-08 | 2025-12-26 |
| Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction LCZ696 (sacubitril/valsartan), Enalapril, Placebo of Enalapril - Heart Failure and Reduced Ejection Fraction | Phase 4 | Completed | Novartis Pharmaceuticals | 465 | 2016-08-17 | 2021-01-05 |
Heart Failure (2) · Heart Failure, Systolic (2)
Cardiovascular Diseases (2) · Heart Diseases (2)
Enalapril (1) · Valsartan (1) · sacubitril (1) · sacubitril and valsartan sodium hydrate drug combination (1)
Gødstrup Hospital (1) · Novartis Pharmaceuticals (1)
Denmark (1) · United States (1)
PMID 31475296, PMID 33663237, PMID 35115085, PMID 35560696, PMID 40678912